Drug intelligence / Profile preview

BPI-3016

Development stage: Phase 1
Lead developer: Betta Pharmaceuticals
Modality: Small Molecules, Peptides, Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

BPI-3016 is a novel, long-acting analogue of human glucagon-like peptide 1 (hGLP-1), developed for the treatment of type 2 diabetes mellitus. It is designed to be administered subcutaneously and acts as a GLP-1 receptor agonist, mimicking the action of endogenous GLP-1 to enhance glucose-dependent insulin secretion. The drug is currently investigational and has been evaluated in phase 1 clinical trials for safety, pharmacokinetics, and pharmacodynamics in healthy subjects[1][4][5]. BPI-3016 is classified as a peptide/protein therapeutic with specific amino acid modifications to prolong its activity[3][4].

Other names: LONG-ACTING GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOG

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on BPI-3016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPI-3016.

Explore the full profile